Table 5.
Completed and ongoing clinical trial of NK cell-based therapy for hematological malignancies
| Cancer type | Therapy | Phase | NCT | Status |
|---|---|---|---|---|
| Acute myeloid leukemia | Allogeneic, IL-2 UCB-NK cells | I/II | NCT04347616 | Ongoing |
| Allogeneic NK cell | I | NCT04220684 | Ongoing | |
| Alloreactive NK cell | N/A | NCT03955848 | Ongoing | |
| Poor prognosis non-AML hematologic malignancies | Allogeneic haploidentical NK cell infusions | I | NCT00697671 |
Completed No outcome reported |
| Refractory non-B lineage hematologic malignancies | Allogeneic haploidentical NK Cell Infusions | I | NCT00640796 |
Completed No outcome reported |
| CD33-positive acute myeloid leukemia | Anti-CD33 CAR-NK cells | I/II | NCT02944162 |
PMID: 28054442 Found to be effective and prevented both tumor relapses and graft versus host disease |
| Acute myeloid leukemia & advanced hematological malignancies | Alloreactive, IL-2 activated NK cells | I/II | NCT01220544 |
Unknown No outcome reported |
| Hematological malignancy patients who received fate therapeutics | Genetically modified NK cell | N/A | NCT04093622 | Ongoing |
| High-risk tumor and lymphoma | Allogeneic haploidentical NK cell infusion combined with autologous stem cell transplantation | I | NCT02130869 |
Completed No outcome reported |
| Pediatric acute leukemia | Activated and expanded NK cells (NKAEs) | II | NCT02074657 |
PMID: 29477379 Found to be safe and feasible |
| Chronic Lymphocytic Leukemia (CLL) | NK cell with rituximab and Rhu-GMCSF | I | NCT00383994 |
Completed No outcome reported |
| NK cell | I | NCT02280525 | Ongoing | |
| CD19 + Leukemia | Allogeneic anti-CD19 CAR-NK cells | I/II | NCT02892695 |
PMID: 28054442 Found major improvements in treating leukemia |
| Multiple myeloma | KIR-ligand mismatched NK cells from a haploidentical donor | I | NCT00089453 |
Completed No outcome reported |
| Acute myeloid leukemia & acute lymphoblastic leukemia | Expanded haploidentical NK cells | I | NCT04327037 | Ongoing |
| Ph + acute lymphoblastic leukemia | Autologous NK cell | I | NCT02185781 |
Unknown No outcome reported |
| Lymphoma, myeloma, and leukemia | HLA-I haplotype mismatched NK cell | I | NCT00660166 |
Completed No outcome reported |
| Chronic myeloid leukemia | NK cell | I/II | NCT03348033 | Enrolling |
| B cell non-Hodgkin’s lymphoma | Cord blood-derived expanded allogeneic NK cells combined with rituximab, high-dose chemotherapy, and stem cell transplant | II | NCT03019640 | Ongoing |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells combined with high-dose chemotherapy and stem cell transplant | I/II | NCT03579927 | Withdrawn | |
| B cell lymphoma | NK cells with rituximab | I/II | NCT02843061 |
Completed No outcome reported |
* Culture medium of every expansion protocol contains IL-2 or more cytokines